Similar to others' findings, we also found that newly-diagnosed CML patients expressed fewer activating receptors (i.e., NKG2D, NKp30, and DNAM-1 in Figure 1A) on their NK cell surface. This evidence concerns the gene NCR3 and chronic myelogenous leukemia, BCR-ABL1 positive.